Diagnostic framework #
Chronic insomnia involves sleep initiation, maintenance or early-waking difficulty despite adequate opportunity, with daytime consequences, at least 3 nights weekly for at least 3 months. Establish the actual sleep window and distinguish insomnia from circadian mismatch, insufficient opportunity and subjective dissatisfaction without impairment.
Targeted clinical assessment #
Use a sleep diary to reconstruct bedtime, attempted sleep, awakenings, final waking, naps and variability. Ask about snoring/apnea, restless legs, pain, nocturia, shift work, caffeine, alcohol and sedatives. Assess mood episodes, distress and next-day sleepiness; document driving or work implications.
Differential diagnosis #
| Alternative / comorbidity | Clinical clue |
|---|---|
| Obstructive sleep apnea | Snoring, witnessed pauses, sleepiness and relevant physical findings. |
| Circadian disorder | Sleep improves when the preferred timing is permitted. |
| Restless legs | Urge to move with rest/evening predominance and relief by movement. |
| Mania | Reduced need for sleep with increased energy, rather than fatigue after poor sleep. |
| Medication/substance effect | Dose timing, stimulants, alcohol and withdrawal may explain the pattern. |
Indicated investigations #
| Indication | Investigation |
|---|---|
| Suspected apnea or another sleep disorder | Refer for appropriate sleep assessment/testing. |
| Specific medical clues | Directed examination and laboratory tests. |
| Uncomplicated insomnia | Diagnosis is usually clinical; polysomnography is not an automatic requirement. |
Treatment sequence #
View treatment map
- Formulation
Treat contributing illness and identify perpetuating sleep behaviors.
- Core treatment
CBT-I: stimulus control, sleep scheduling/restriction, cognitive work and counter-arousal methods.
- Selected medication
Match the drug to sleep onset/maintenance complaints and individual risks; document the review plan.
- Persistent difficulty
Check delivery and adherence to CBT-I, other sleep disorders and sedative burden.
| Step | Approach |
|---|---|
| Formulation | Treat contributing illness and identify perpetuating sleep behaviors. |
| Core treatment | CBT-I: stimulus control, sleep scheduling/restriction, cognitive work and counter-arousal methods. |
| Selected medication | Match the drug to sleep onset/maintenance complaints and individual risks; document the review plan. |
| Persistent difficulty | Check delivery and adherence to CBT-I, other sleep disorders and sedative burden. |
Doses & prescribing #
Each prescribing record identifies its population and source jurisdiction; international labeling does not establish Indian approval. The clinician selects treatment after assessment.
Doxepin
Sleep-maintenance insomnia: low-dose insomnia tablets
Adults · Low-dose 3 mg / 6 mg insomnia tablets; not antidepressant-strength capsules · Oral · United States product labeling
- Starting dose
- 6 mg at bedtime for adults; 3 mg may be appropriate. Age ≥65: start 3 mg.
- Titration
- If indicated and tolerated, increase a 3 mg dose to 6 mg; no mandatory escalation.
- Treatment range / target
- 3–6 mg once nightly, within 30 minutes of bedtime; avoid within 3 hours of a meal.
- Maximum / limits
- 6 mg/day; with cimetidine, maximum 3 mg/day.
- Trial & duration
- Reevaluate persistent symptoms; failure to remit after 7–10 days may indicate an underlying disorder.
- Monitoring
- Next-day sedation, impaired alertness, falls and complex sleep behaviors.
- Population & organ-function adjustments
- Hepatic impairment or urinary-retention tendency: start 3 mg. Older adults start 3 mg.
- Important cautions
- Contraindicated in untreated narrow-angle glaucoma or severe urinary retention and with MAOIs. Avoid alcohol/additive sedatives.
Nonresponse & escalation #
Reassess the diagnosis, schedule, naps, inconsistent wake time and treatment adherence before adding sedatives. Persistent sleepiness suggests a different or additional problem. Check whether CBT-I was actually delivered rather than recording sleep-hygiene advice as an adequate course.
Maintenance & discontinuation #
Maintain a consistent wake time and the behavioral skills learned during treatment. Review ongoing hypnotic need, next-day effects and dependence/withdrawal potential for the selected drug. Benzodiazepine or Z-drug discontinuation requires an individualized plan; the low-dose doxepin record is not a tapering protocol for those drugs.
Special populations & comorbidity #
Older adults and patients with falls, apnea, respiratory disease, cognitive impairment or interacting sedatives require particular caution. Pregnancy/lactation and hepatic impairment need product-specific review. Adapt sleep scheduling when bipolar activation, seizure vulnerability or safety-critical work changes the risk.
Follow-up #
Review the diary, daytime function and adverse effects, not only total reported sleep. With low-dose doxepin, reassess insomnia persisting after 7–10 days for a comorbid or alternative disorder. Record the expected review date whenever a hypnotic is started.
Clinical pitfalls #
Do not assume antidepressant-strength doxepin capsules share the low-dose insomnia regimen. Avoid stacking sedatives to treat unrecognized apnea or circadian mismatch. Longer time in bed can perpetuate insomnia rather than restore sleep.
Assessment tools #
Choose the instrument for its intended purpose; interpretation accompanies the linked tool.
Patient discussion #
Open a plain-language explanation
Assessment looks at both night-time patterns and daytime effects. A structured approach can change habits and beliefs that keep insomnia going.
References · 4
- NHLBI: Insomnia diagnosis · United States · Checked 2026-10-26 · Supports: Diagnostic framework; Targeted clinical assessment; Differential diagnosis; Indicated investigations
- VA/DoD: Behavioral and psychological insomnia treatments, 2025 · United States · Checked 2026-10-26 · Supports: Treatment sequence; Nonresponse & escalation; Maintenance & discontinuation; Special populations & comorbidity; Clinical pitfalls
- AASM: Pharmacological treatment of chronic insomnia · United States specialty guideline · Checked 2026-10-26 · Supports: Treatment sequence; Maintenance & discontinuation
- Low-dose doxepin tablets: product label · United States label · Checked 2026-10-26 · Supports: Special populations & comorbidity; Follow-up; Clinical pitfalls; Doxepin — Sleep-maintenance insomnia: low-dose insomnia tablets (Low-dose 3 mg / 6 mg insomnia tablets; not antidepressant-strength capsules)